Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Psychosom Med ; 80(4): 370-376, 2018 05.
Article in English | MEDLINE | ID: mdl-29521882

ABSTRACT

OBJECTIVE: Although catatonia can occur secondary to a general medical condition, catatonia itself has been known to lead to various medical compolications. Although case reports on the association of catatonia with subsequent medical complications have been documented, no comprehensive large-scale study has been performed. To investigate specific medical complications after catatonia, we conducted a retrospective cohort study of specific medical complications of schizophrenia patients with catatonia. METHODS: The 1719 schizophrenia inpatients in our study were categorized into two groups: the catatonia group, i.e., those who exhibited catatonic stupor while they were hospitalized, and the noncatatonia group, i.e., those who never exhibited catatonic stupor. Differences between the two groups in the occurrence of subsequent medical complications were examined using linear and logistic regression analyses, and models were adjusted for potentially confounding factors. RESULTS: The catatonia group had an increased risk for mortality (odds ratio = 4.8, 95% confidence interval = 2.0-10.6, p < .01) and certain specific medical complications, i.e., pneumonia, urinary tract infection, sepsis, disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep venous thrombosis, pulmonary embolism, urinary retention, decubitus, arrhythmia, renal failure, neuroleptic malignant syndrome, hypernatremia, and liver dysfunction (all p values < .01, except for deep venous thrombosis, p = .04 in the multiple linear regression analysis). CONCLUSIONS: Catatonic stupor in schizophrenia substantially raises the risk for specific medical complications and mortality. Hyperactivity of the sympathetic nervous system, dehydration, and immobility, which are frequently involved in catatonia, might contribute to these specific medical complications. In catatonia, meticulous care for both mental and medical conditions should be taken to reduce the risk of adverse medical consequences.


Subject(s)
Catatonia , Psychotic Disorders , Schizophrenia , Stupor , Adult , Catatonia/complications , Catatonia/mortality , Catatonia/physiopathology , Female , Humans , Male , Middle Aged , Psychotic Disorders/complications , Psychotic Disorders/mortality , Psychotic Disorders/physiopathology , Retrospective Studies , Schizophrenia/complications , Schizophrenia/mortality , Schizophrenia/physiopathology , Stupor/complications , Stupor/mortality , Stupor/physiopathology
2.
Crit Care Med ; 42(3): e234-41, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24275514

ABSTRACT

OBJECTIVE: Catatonia is a neuropsychiatric syndrome with motor and behavioral symptoms occurring in patients with or without a history of psychiatric illness. Although it is associated with significant morbidity and mortality, the prevalence of catatonia in the ICU setting is unknown. The diagnosis and management of catatonia in the critically ill patient raises unique challenges. Furthermore, the diagnosis and management are not included in most critical care curricula. The objective of this retrospective study is to increase the awareness of this clinically important condition among critical care providers. DESIGN: Retrospective case series study. SETTING: Multiple critical care units at a university-affiliated tertiary care hospital. PATIENTS: Five critically ill patients with catatonia, aged 17 to 78. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: All notes, laboratory data, imaging results, other diagnostic studies, therapeutic interventions, and responses to treatment were reviewed for five critically ill patients with catatonia. No unifying cause of catatonia or predisposing conditions were identified for these patients. Currently available diagnostic criteria for catatonia were found to be nonspecific in the ICU setting. New diagnostic criteria for catatonia specific to the critically ill patient are proposed. CONCLUSIONS: Catatonia can occur in a wide variety of critical care settings, with or without precedent psychiatric illness, and it may be exacerbated or induced by common intensive care practices. Psychomotor findings are imperative in examination of critically ill patients with altered mental status in order to diagnose catatonia.


Subject(s)
Catatonia/diagnosis , Catatonia/drug therapy , Intensive Care Units , Lorazepam/therapeutic use , Adolescent , Aged , Anti-Anxiety Agents/therapeutic use , Blood Chemical Analysis , Catatonia/mortality , Critical Illness/mortality , Critical Illness/therapy , Early Diagnosis , Electroencephalography/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neuropsychological Tests , Retrospective Studies , Risk Assessment , Sampling Studies , Severity of Illness Index , Survival Rate , Treatment Outcome
3.
Gen Hosp Psychiatry ; 32(6): 631-5, 2010.
Article in English | MEDLINE | ID: mdl-21112456

ABSTRACT

OBJECTIVE: To analyze clinical characteristics, time lag between diagnosis and treatment, and outcome of patients treated for catatonia, with the intention to improve daily clinical care. METHOD: A retrospective case study. RESULTS: Between 1991 and 2009, a total of 34 patients were clinically diagnosed to have benign catatonia (n=13), malignant catatonia (n=11) and neuroleptic malignant syndrome (n=10). A total of 63 additional psychiatric diagnoses were present, and half of the patients had comorbid medical and neurological disorders. The mean time lags between first catatonic symptoms and first treatment and between first catatonic symptoms and second treatment were 15±36 and 58±92 days, respectively. Of the 34 patients, 26 (76%) improved, with complete remission in 20 (58%); mortality rate was 9% (n=3). CONCLUSIONS: Retrospective evaluation of 34 catatonic patients revealed a great variety of psychiatric diagnoses and somatic comorbidity. Although treatment was effective in 76%, time lag between the first symptoms and effective treatment was remarkably long. Based on our retrospective critical evaluation, a clinical protocol has been developed to improve daily care for these complex and very ill patients.


Subject(s)
Catatonia/therapy , Neuroleptic Malignant Syndrome/therapy , Adult , Amantadine/therapeutic use , Benzodiazepines/therapeutic use , Bromocriptine/therapeutic use , Catatonia/diagnosis , Catatonia/mortality , Catatonia/psychology , Cause of Death , Comorbidity , Dantrolene/therapeutic use , Delayed Diagnosis , Electroconvulsive Therapy , Female , Humans , Length of Stay/statistics & numerical data , Male , Mental Disorders/diagnosis , Mental Disorders/mortality , Mental Disorders/psychology , Mental Disorders/therapy , Middle Aged , Neuroleptic Malignant Syndrome/diagnosis , Neuroleptic Malignant Syndrome/epidemiology , Neuroleptic Malignant Syndrome/mortality , Neuroleptic Malignant Syndrome/psychology , Retrospective Studies , Survival Analysis
4.
Schizophr Res ; 113(2-3): 233-40, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19443182

ABSTRACT

This paper examined outcomes among youth with catatonic syndrome and determined whether the characteristics suggesting the relevance of chronic catatonic schizophrenia (CCS) at index episode remained stable at follow-up. From 1993 to 2004, 35 individuals aged 12 to 18 years were prospectively admitted for management of catatonic syndrome and followed up after discharge. Mean duration from discharge to follow-up was 3.9 years (range 1-10). Four patients were lost to follow-up. Among the remaining 31 subjects (mean age=19.5 years, range 15-26), life-time diagnosis using the Diagnostic Interview for Genetic Studies was unchanged in 28 patients, and included schizophrenia (all subtypes; N=20), major depressive episode (N=5), bipolar disorder type I (N=4) and brief psychotic episode (N=2). Mortality (all-cause Standardized Mortality Ratio=6266; 95% CI=1181-18,547) and morbidity were severe, with 3 deaths (including 2 suicides), 6 patients presenting with a causal organic condition and 14 subjects needing continuous psychiatric care. All males in the study (N=8) who had chronic catatonic schizophrenia at the index episode still had chronic catatonic signs at follow-up. Catatonia is one of the most severe psychiatric syndromes in adolescents. It is associated with a 60-fold increased risk of premature death, including suicide, when compared to the general population of same sex and age. This increased risk of premature death remains higher than the one measured in former adolescent psychiatric patients (all-cause SMR=221; 95% CI=156-303; Engqvist and Rydelius, 2006), or in schizophrenia irrespective to age and subtype (all-cause SMR=157; 95% CI=153-160; Harris and Barraclough, 1998).


Subject(s)
Catatonia/epidemiology , Catatonia/mortality , Adolescent , Adult , Catatonia/diagnosis , Female , Follow-Up Studies , Humans , Male , Morbidity , Prospective Studies , Psychiatric Status Rating Scales , Psychometrics , Retrospective Studies , Risk Factors , Severity of Illness Index , Sex Factors , Socioeconomic Factors , Young Adult
6.
Encephale ; 27(3): 213-6, 2001.
Article in French | MEDLINE | ID: mdl-11488250

ABSTRACT

Lethal catatonia continues to occur and represents a nonspecific syndrome associated with diverse organic as well as functional conditions. From this perspective, neuroleptic malignant syndrome may be conceptualized as a neuroleptic-induced toxic or iatrogenic form of organic lethal catatonia. Neuroleptics appear ineffective in the treatment of lethal catatonia and should be stopped whenever this disorder is suspected. Existing data suggest that ECT is a safe and effective treatment for lethal catatonia. ECT also appears effective in the treatment of neuroleptic malignant syndrome.


Subject(s)
Antipsychotic Agents/therapeutic use , Catatonia/therapy , Electroconvulsive Therapy , Antipsychotic Agents/adverse effects , Catatonia/etiology , Catatonia/mortality , Humans , Neuroleptic Malignant Syndrome/diagnosis , Neuroleptic Malignant Syndrome/mortality , Neuroleptic Malignant Syndrome/therapy , Prognosis , Survival Rate
7.
Rev. argent. anestesiol ; 59(1): 32-9, ene.-feb. 2001. tab, graf
Article in Spanish | LILACS | ID: lil-288446

ABSTRACT

El Síndrome Neuroléptico Maligno es una enfermedad rara pero con alta mortalidad, por lo cual es conveniente tenerla presente ante la aparición de un cuadro de hipertermia inducido por drogas. En ocasiones la presentación clínica suele ser indistinguible de una Hipertermia Maligna, si bien su mecanismo fisiopatológico es completamente diferente. Sus características clínicas comprenden hipertermia, rigidez muscular, elevación de la creatininfosfoquinasa (C.P.K.) además de mioglobinemia y mioglobinuria, como consecuencia de la rabdomiólisis. En esta recopilación mencionaremos su fisiopatología, etiología, criterios clínicos, su relación con Hipertermia maligna y los detalles de su tratamiento.


Subject(s)
Humans , Diagnosis, Differential , Dopamine Antagonists/adverse effects , Hyperthermia, Induced/adverse effects , Hyperthermia, Induced/mortality , Recurrence , Neuroleptic Malignant Syndrome/etiology , Neuroleptic Malignant Syndrome/physiopathology , Neuroleptic Malignant Syndrome/therapy , Antipsychotic Agents , Antipsychotic Agents/adverse effects , Cholinergic Antagonists/toxicity , Catatonia/diagnosis , Catatonia/mortality , Dantrolene/therapeutic use , Encephalitis, Viral/diagnosis , Muscle Rigidity/etiology , Risk Factors , Serotonin Syndrome/congenital
8.
Rev. argent. anestesiol ; 59(1): 32-9, ene.-feb. 2001. tab, graf
Article in Spanish | BINACIS | ID: bin-10179

ABSTRACT

El Síndrome Neuroléptico Maligno es una enfermedad rara pero con alta mortalidad, por lo cual es conveniente tenerla presente ante la aparición de un cuadro de hipertermia inducido por drogas. En ocasiones la presentación clínica suele ser indistinguible de una Hipertermia Maligna, si bien su mecanismo fisiopatológico es completamente diferente. Sus características clínicas comprenden hipertermia, rigidez muscular, elevación de la creatininfosfoquinasa (C.P.K.) además de mioglobinemia y mioglobinuria, como consecuencia de la rabdomiólisis. En esta recopilación mencionaremos su fisiopatología, etiología, criterios clínicos, su relación con Hipertermia maligna y los detalles de su tratamiento. (AU)


Subject(s)
Humans , Neuroleptic Malignant Syndrome/etiology , Neuroleptic Malignant Syndrome/physiopathology , Neuroleptic Malignant Syndrome/therapy , Hyperthermia, Induced/adverse effects , Hyperthermia, Induced/mortality , Dopamine Antagonists/adverse effects , Diagnosis, Differential , Recurrence , Muscle Rigidity/etiology , Dantrolene/therapeutic use , Antipsychotic Agents , Antipsychotic Agents/adverse effects , Risk Factors , Catatonia/diagnosis , Catatonia/mortality , Serotonin Syndrome/congenital , Encephalitis, Viral/diagnosis , Cholinergic Antagonists/toxicity
9.
J Clin Psychopharmacol ; 20(2): 257-9, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10770467

ABSTRACT

Neuroleptic malignant syndrome (NMS) is usually a self-limited disorder, with most cases resolving within 2 weeks after antipsychotic drug discontinuation. However, the course of NMS may not always be short-lived. In this report, the authors describe five patients who developed a residual catatonic state that persisted after acute hyperthermic symptoms of NMS had subsided and compare them with 27 similar cases in the literature. Two of our patients recovered gradually with supportive treatment. Three patients were treated with electroconvulsive therapy (ECT). Of these, two showed a positive response, although one died later of intercurrent pneumonia. A third patient did not respond to ECT, but recovered gradually thereafter. Although dopamine agonists or benzodiazepines have been advocated for the treatment of residual symptoms in previous case reports, ECT was the treatment most often associated with a rapid response and no mortality, even in patients refractory to pharmacotherapy. In conclusion, catatonic and parkinsonian symptoms of NMS may persist as a residual state lasting for weeks to months after more fulminant acute symptoms abate. These residual symptoms may be more likely to develop in patients with pre-existing structural brain disorders. Although patients may improve gradually with supportive care or pharmacotherapy, ECT can often be highly effective in treating the residual catatonic state that follows NMS.


Subject(s)
Antipsychotic Agents/adverse effects , Catatonia/chemically induced , Neuroleptic Malignant Syndrome/diagnosis , Substance Withdrawal Syndrome/diagnosis , Adult , Aged , Antipsychotic Agents/therapeutic use , Catatonia/diagnosis , Catatonia/mortality , Catatonia/therapy , Electroconvulsive Therapy , Female , Humans , Male , Middle Aged , Neuroleptic Malignant Syndrome/mortality , Neuroleptic Malignant Syndrome/therapy , Neurologic Examination/drug effects , Substance Withdrawal Syndrome/mortality , Substance Withdrawal Syndrome/therapy , Survival Rate , Treatment Outcome
10.
J Clin Psychiatry ; 56(1): 21-5, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7836335

ABSTRACT

BACKGROUND: Catatonia is associated with excess early mortality when it is unrecognized or inadequately treated. The characteristics of the lethal catatonia subtype are now well described, but the excess mortality of the remaining patients with catatonic syndrome, particularly from pulmonary embolism, appears to be inadequately recognized. The fatal risk of the catatonic syndrome is reviewed. METHOD: Two new case reports of sudden death from pulmonary embolism in catatonic syndrome are presented. The world literature on morbidity, mortality, and pulmonary embolism in catatonia was reviewed by a search of MEDLINE and PsychInfo from 1966 to the present. Additional older references were discovered by screening bibliographies from articles produced by the searches. RESULTS: Twenty cases of autopsy-confirmed pulmonary embolism were found in patients with catatonic syndrome. Catatonic patients were more likely to die of pulmonary embolism and die earlier than patients with other types of schizophrenia. Death from pulmonary embolism did not occur until after the second week of catatonic symptoms and often occurred without warning. CONCLUSION: Risk of a fatal pulmonary embolism is inherent in persistent catatonic symptoms and may explain the observed excess early mortality. Prompt resolution of the catatonic syndrome with benzodiazepines, barbiturates, or electroconvulsive therapy is the best way to reduce risk of pulmonary embolism. The prophylactic value of physical therapy or anticoagulation merits further investigation. Despite the absence of controlled trials of treatment effectiveness, the catastrophic outcome of acute pulmonary embolism warrants early and vigorous intervention in catatonic patients.


Subject(s)
Catatonia/mortality , Pulmonary Embolism/mortality , Adult , Catatonia/epidemiology , Cause of Death , Comorbidity , Death, Sudden/epidemiology , Female , Humans , Pulmonary Embolism/epidemiology , Risk Factors , Schizophrenia, Catatonic/epidemiology , Schizophrenia, Catatonic/mortality , Syndrome
11.
Arch Gen Psychiatry ; 43(9): 839-48, 1986 Sep.
Article in English | MEDLINE | ID: mdl-2875701

ABSTRACT

From 39 reported cases of the "neuroleptic malignant syndrome," three groups were identified: those with concurrent medical problems that could cause fever that accompanied the extrapyramidal symptoms; those with medical problems less clearly related to fever; and those without other medical disorders. Dehydration, infection, pulmonary embolus, and rhabdomyolysis were the common complications of untreated extrapyramidal symptoms. Three patients died, all with medical complications. In 14 cases, no medical cause of fever was identified. Hypotheses about mechanisms for fever include psychiatric illness, disruption of dopaminergic aspects of thermoregulation, and peripheral and central effects on muscle contraction leading to excess heat production. Neuroleptic-induced rigidity should be treated vigorously, with prompt discontinuation of neuroleptic therapy and administration of dopamine agonists in severe cases with or without fever. The cases of extrapyramidal symptoms with fever are too heterogeneous to justify the assumption of a unitary and "malignant" syndrome.


Subject(s)
Antipsychotic Agents/adverse effects , Basal Ganglia Diseases/chemically induced , Fever/chemically induced , Neuroleptic Malignant Syndrome/diagnosis , Adolescent , Adult , Aged , Basal Ganglia Diseases/diagnosis , Basal Ganglia Diseases/mortality , Body Temperature Regulation/drug effects , Catatonia/diagnosis , Catatonia/mortality , Child , Child, Preschool , Diagnosis, Differential , Female , Fever/diagnosis , Fever/mortality , Humans , Male , Middle Aged , Muscle Contraction/drug effects , Neuroleptic Malignant Syndrome/mortality , Receptors, Dopamine/drug effects
12.
Encephale ; 9(4): 365-85, 1983.
Article in French | MEDLINE | ID: mdl-6142817

ABSTRACT

After a review of the literature centered on the possible relationship of acute psychiatric symptomatology and death, more specifically in relation with acute catatonia, the writers examine all cases of schizophrenic patients admitted to the Psychiatric University Hospital of Lausanne (Hôpital de Cery) during the period from 1961 to 1981. The importance of acute catatonia is discussed and compared to other similar syndromes (the porcine stress syndrome, malignant hyperthermia, the neuroleptic "malignant" syndrome).


Subject(s)
Catatonia/physiopathology , Schizophrenia, Catatonic/physiopathology , Acute Disease , Adolescent , Adult , Antipsychotic Agents/adverse effects , Basal Ganglia Diseases/chemically induced , Catatonia/chemically induced , Catatonia/mortality , Delusions/etiology , Female , Humans , Male , Middle Aged , Schizophrenia, Catatonic/diagnosis , Stress, Physiological
SELECTION OF CITATIONS
SEARCH DETAIL